June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Targeted delivery of triamcinolone acetonide and CLS011A to the posterior ocular tissues via suprachoroidal administration
Author Affiliations & Notes
  • Brian Burke
    Clearside Biomedical, Alpharetta, Georgia, United States
  • Samirkumar Rajnikant Patel
    Clearside Biomedical, Alpharetta, Georgia, United States
  • Donna Taraborelli
    Clearside Biomedical, Alpharetta, Georgia, United States
  • Craig B Struble
    Covance, Madison, Wisconsin, United States
  • Glenn Noronha
    Clearside Biomedical, Alpharetta, Georgia, United States
  • Footnotes
    Commercial Relationships   Brian Burke, Clearside Biomedical (E); Samirkumar Patel, Clearside Biomedical (E); Donna Taraborelli, Clearside Biomedical (E); Craig Struble, None; Glenn Noronha, Clearside Biomedical (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4112. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Brian Burke, Samirkumar Rajnikant Patel, Donna Taraborelli, Craig B Struble, Glenn Noronha; Targeted delivery of triamcinolone acetonide and CLS011A to the posterior ocular tissues via suprachoroidal administration. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4112.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Data for the ocular distribution of two drugs, triamcinolone acetonide (TA, corticosteroid) and CLS011A (tyrosine kinase inhibitor) following suprachoroidal administration in rabbit eyes, will be presented.

Methods : Suprachoroidal and intravitreal administration of TA (40 mg/mL) was performed bilaterally into rabbit eyes. An additional group of animals were injected with a proprietary aqueous suspension of CLS011A (40 mg/mL) into the suprachoroidal space (SCS). Animals (n=2/time point) were sacrificed on at least 5 time points within 91 days. Ocular tissues (sclera/choroid/retinal pigment epithelium: SCR, retina, vitreous, iris-ciliary body: ICB, aqueous, and lens) and plasma were collected for quantification of drug concentrations. Analyses were performed using high performance liquid chromatography assays.

Results : TA was detectable throughout the 91 day period in eyes dosed by either suprachoroidal or intravitreal administration. Based on area under the curve analysis, 96% of the drug was exposed to SCR and retina after SCS administration, in comparison to 20% in these tissues following intravitreal administration (IVT). Retinal exposure was similar between the two groups: 19% SCS vs 15% IVT. A large difference was seen in the ICB exposure: <1% SCS vs 25% IVT. Results from suprachoroidal CLS011A showed drug levels in the SCR that were at least 3 orders of magnitude higher than vitreous and drug was below limits of detection (1 ng/mL) in the aqueous. These relative distribution levels for each drug were maintained during the 3 month study period.

Conclusions : Suprachoroidal administration of TA and CLS011A were targeted to the SCR and retina and targeting was maintained over 3 months. These data might have implications for a better therapeutic and/or safety profile for the treatment of chorio-retinal diseases.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.